125733037.cms .png

WHO issues guidelines on GLP-1 therapies for obesity treatment: Understanding the impact, safety considerations, and who can benefit

This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity treatment. Released on December 1, 2025, the document conditionally recommends drugs like semaglutide, liraglutide, and tirzepatide for adults with a BMI of 30 or higher-but only as part of a lifelong plan that pairs them…

Read More
1764308259 1.jpg

How to improve blood circulation in legs naturally: Causes, lifestyle tips, and effective therapies

Maintaining good, natural blood circulation in the legs, is important as part of overall vascular health, to prevent such complications as swelling, pain, and varicose veins that can affect life quality. Evidence-based natural approaches include exercise, diet, lifestyle modifications, and therapies that support vascular function and enhance blood flow. (Source: British Heart Foundation) What are…

Read More
1763889293 pic 10.jpg

India reviews drug imports: Over 65 patented therapies flagged; agencies seek key cancer, diabetes and cardiac drugs

The government is considering a plan to allow global tenders for a wide range of patented medicines — spanning weight-loss, cancer, cardiac and diabetes treatments — to support procurement for central healthcare agencies such as the armed forces’ medical services and the Employees’ State Insurance Corporation (ESIS).The plan is aimed at securing essential treatments that…

Read More
1762186459 unnamed file.jpg

Bharat Biotech forays into CRDMO space with new cell & gene therapies arm Nucelion Therapeutics

HYDERABAD: Vaccine maker Bharat Biotech is foraying into the contract research development and manufacturing organisation (CDRMO) space with the setting up of a new wholly-owned subsidiary, Nucelion Therapeutics Pvt Ltd, that is focused on cell and gene therapies (CGT).Announcing its entry into this high growth CRDMO segment, Bharat Biotech said the new entity will support…

Read More